Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).
Scribe projected to enter the clinic in mid-2026 with STX-1150, a PCSK9-targeting CRISPR epigenetic silencing therapy for durable LDL-C reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results